Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas
Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ B-cell non-Hodgkin lymphomas
复制标题
新型抗 CD20 单克隆抗体与利妥昔单抗用于 CD20 B 细胞非霍奇金淋巴瘤诱导治疗的疗效和安全性
作者：
Chengxin Luo;Guixian Wu;Xiangtao Huang;Yanni Ma;Yali Zhang;Qiuyue Song;Mingling Xie;Yanni Sun;Yarui Huang;Zhen Huang;Yu Hou;Shuangnian Xu;Jieping Chen;Xi Li
